Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

JAGXBullishCorporate Developmentsnews

High materiality7/10

FDA Waiver for Mytesi PDUFA 2027; MVID NDA Target Mid-2027

Sep 22, 2026, 9:53 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Waived PDUFA reduces near-term cost burden; mid-2027 MVID NDA target provides a tangible catalyst. This complements existing Mytesi commercialization and crofelemer pipeline, potentially re-rating JAGX if milestones hold, despite typical biotech regulatory risk.

AI summary

What happened, with direct paths to the underlying reporting

Jaguar Health's Napo Pharmaceuticals announced FDA's PDUFA fee waiver for Mytesi in 2027, reducing NDA costs. The firm remains focused on MVID and SBS crofelemer powder with a mid-2027 NDA target. If the timeline holds and development progresses as planned, it could act as a positive catalyst for JAGX through 2027.

FDA waived PDUFA fee for Mytesi for 2027. NDA costs in 2027 reduced.
NDA filing for MVID targeted mid-2027. Pipeline momentum remains a driver.
Mytesi approved for noninfectious diarrhea in HIV on ART; marketed by Future Pak.
Focus remains on crofelemer powder for SBS/MVID across global development.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

FDA Waiver for Mytesi PDUFA 2027; MVID NDA Target Mid-2027

Jaguar Health Gains on Progress in Pediatric Disease Treatment

Small-cap biotech Jaguar Health’s stock jumps 7% as it launches treatment for oral mucositis in cancer patients - MarketWatch